Keywords: antisoma, gains, rights, bc1-il12, uk-based, biopharmaceutical, firm
Antisoma gains rights to BC1-IL12
Article | 02 August 2004
UK-based Antisoma, a biopharmaceutical firm specializing in thedevelopment of novel anticancer drugs, has gained exclusive rights to BC1-IL12. This ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
